cardiovascular system
• increased cross-sectional area without change in length in tamoxifen-treated mice
|
• in tamoxifen-treated mice
• however, overexpression of a phosphorylation-mimic mutant of NEXN (S437E) rescues cardiac hypertrophy
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
• however, overexpression of a phosphorylation-mimic mutant of NEXN (S437E) rescues fibrosis
|
• rapid onset in tamoxifen-treated mice with decreased left ventricular internal diameter, diastole, and a significant decrease in the left ventricular ejection fraction
|
growth/size/body
• in tamoxifen-treated mice
• however, overexpression of a phosphorylation-mimic mutant of NEXN (S437E) rescues cardiac hypertrophy
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
muscle
• increased cross-sectional area without change in length in tamoxifen-treated mice
|
• in tamoxifen-treated mice
• however, overexpression of a phosphorylation-mimic mutant of NEXN (S437E) rescues cardiac hypertrophy
|
• disrupted integrity ruptured myofilaments, blurred Z-disk, and mitochondrial abnormalities in cardiomyocytes of tamoxifen-treated mice
|
• in cardiomyocytes of tamoxifen-treated mice
|
respiratory system
• in tamoxifen-treated mice
|
cellular
• in tamoxifen-treated mice
• however, overexpression of a phosphorylation-mimic mutant of NEXN (S437E) rescues fibrosis
|